| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2850502 | American Heart Journal | 2010 | 7 Pages |
Abstract
By evaluating the use of apixaban as a replacement for ASA in AF patients who are not treated with a VKA, the AVERROES study is addressing an important unmet clinical need. The results of AVERROES will be complementary to those of a parallel noninferiority trial comparing apixaban with VKA therapy in patients with AF who are able to receive a VKA.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
John W. Eikelboom, Martin O'Donnell, Salim Yusuf, Rafael Diaz, Greg Flaker, Robert Hart, Stefan Hohnloser, Campbell Joyner, Jack Lawrence, Prem Pais, Janice Pogue, David Synhorst, Stuart J. Connolly,